Shopping Cart
- Remove All
Your shopping cart is currently empty
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and
ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,270 | 10-14 weeks | |
| 50 mg | $2,980 | 10-14 weeks | |
| 100 mg | $4,000 | 10-14 weeks |
| Description | LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. |
| Molecular Weight | 448.44 |
| Formula | C21H23F3N6O2 |
| Cas No. | 1998714-25-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.